SIGA Technologies Market Research Report

Company Overview

• Name: SIGA Technologies

• Mission: Protecting humanity against some of the world’s more severe infectious diseases, with a focus on developing medicines to prevent and treat emerging infectious diseases with high unmet medical needs.

• Founded and Key People:

• CEO: Diem Nguyen, Ph.D., M.B.A.

• CFO: Daniel J. Luckshire, M.B.A.

• Chief Scientific Officer: Dennis E. Hruby, Ph.D.

• General Counsel: Larry Miller

• SVP, Operations & Chief Supply Chain Officer: Tove’ C. Bolken

• Board Members include: Jaymie Durnan, Harold Ford, Jr., Evan Knisely, Joseph W. “Chip” Marshall III, Dr. Gary Nabel, Julian Nemirovsky, Dr. Holly Phillips, among others.

• Headquarters: 31 East 62nd Street, New York, NY 10065 and Development Operations in Corvallis, OR.

• Employees: 45

• Revenue: $140 million in 2023

• Industry Position: Leader in global health dedicated to combating severe infectious diseases, especially those that cannot be treated by vaccines alone, such as smallpox and mpox (monkeypox).

Products

TPOXX® (Tecovirimat)

• Description: A best-in-class antiviral product targeting orthopoxviruses, including smallpox.

• Key Features:

• Mechanism: Inhibits activity of VP37 protein found on orthopoxviruses, preventing the virus from leaving infected cells.

• Formulations: Available as both oral and intravenous formulations approved by FDA for treatment of smallpox. Known as Tecovirimat-SIGA in the EU and UK for treating smallpox, mpox, cowpox, and vaccinia complications.

• Safety: Proven to be safe and well-tolerated, based on a strong safety profile and targeted nature.

Recent Developments

• Regulatory Milestones:

• TPOXX oral has FDA approval for smallpox treatment in the U.S., and similar approvals in Canada and the EU.

• TPOXX is under consideration for new indications and formulations, including post-exposure prophylaxis and pediatric formulations.

• Clinical Trials and Studies:

• Ongoing trials and studies, including STOMP, for mpox treatment using TPOXX.

• Contracts and Partnerships:

• Awarded a new contract by the U.S. Department of Defense for $9 million worth of TPOXX.

• Agreement to supply TPOXX to Morocco.

• Long-standing partnership with the U.S. government for Strategic National Stockpile.

• Collaborations: Strong global cooperation network with 25+ countries to combat orthopoxvirus outbreaks.

This report summarizes SIGA Technologies' standing as a healthcare leader, underscoring its achievements and developments in the antiviral domain, specifically targeting smallpox and other orthopoxvirus threats.